AstraZeneca and Daiichi Sankyo’s Enhertu should not be made available via the NHS for HER2-low metastatic or unresectable breast cancer after chemotherapy, according to provisional guidance from ...
Hosted on MSN1mon
FDA Expands Label of AZN's Enhertu for New Breast Cancer IndicationAlso, treatment with Enhertu in patients with HER2-low expression led to progression-free survival (PFS) of 13.2 months as compared to 8.1 months for chemotherapy. This was the primary endpoint of ...
NICE and drugmakers AstraZeneca and Daiichi Sankyo have all expressed their disappointment at being unable to agree on a price for Enhertu that would allow it to be used on the NHS for people with ...
Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback